Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM.
Juyeun LeeKristen E KayMichael A VogelbaumJustin D LathiaPublished in: Cancer immunology research (2023)
Enhancing T-cell infiltration into glioblastoma (GBM) tumors has proven challenging yet remains crucial for improving the efficacy of immunotherapy for patients with this deadly cancer. In this issue, Qin, Huang, Li, and colleagues find that inhibiting vasculature formation driven by cancer stem cells is a promising target to enhance immunotherapy in GBM. See related article by Qin et al. (2).